HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tissue plasminogen activator for neonatal coronary thrombosis presenting with mitral valve regurgitation and impaired ventricular function.

AbstractOBJECTIVE:
Neonatal coronary thrombosis is a rarely reported disorder, with variable outcomes described. This study assessed the feasibility and safety of an institutional protocol using tissue plasminogen activator (tPA) administration for the treatment of neonatal coronary artery thrombi.
METHODS:
They reviewed the outcome of three neonates with clinical evidence of myocardial infarction secondary to coronary thrombosis. All three underwent the tPA treatment protocol.
RESULTS:
The three described cases presented at 5 hours, 15 hours, and 10 days of life. The patients identified underwent the tPA protocol at least once. There was clinical evidence of improvement in coronary flow, as well as demonstration of increased left ventricular function and decreased mitral regurgitation. No major adverse events occurred.
CONCLUSION:
Thrombolytic therapy with this tPA protocol may be safe and effective in treating neonates with coronary thrombosis.
AuthorsDelaram Molkara, Jose A Silva Sepulveda, Thomas Do, Christopher Davis, Gregory P Goldstein, John W Moore, Howaida G El-Said
JournalCongenital heart disease (Congenit Heart Dis) Vol. 12 Issue 3 Pg. 270-274 (May 2017) ISSN: 1747-0803 [Electronic] United States
PMID28140523 (Publication Type: Case Reports, Journal Article, Review)
Copyright© 2017 Wiley Periodicals, Inc.
Chemical References
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
Topics
  • Cardiac Catheterization
  • Coronary Angiography
  • Coronary Thrombosis (complications, diagnosis, drug therapy)
  • Dose-Response Relationship, Drug
  • Echocardiography
  • Electrocardiography
  • Female
  • Fibrinolytic Agents (administration & dosage)
  • Humans
  • Infant, Newborn
  • Male
  • Mitral Valve Insufficiency (diagnosis, etiology, physiopathology)
  • Thrombolytic Therapy (methods)
  • Tissue Plasminogen Activator (administration & dosage)
  • Ventricular Dysfunction, Left (diagnosis, etiology, physiopathology)
  • Ventricular Function, Left (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: